News

Novo Nordisk expands lawsuits against weight-loss drug compounders
Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of ...
How Novo Nordisk Gave Up Its Weight-Loss Gains
Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss.
Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?
The deal was Novo Nordisk’s bid to grab back market share from the cheaper, knockoff versions that Hims & Hers and other ...
Novo Nordisk Is Now A Better Value Play Than Eli Lilly With Solid Upside
Novo Nordisk is misunderstood by the market, creating a rare asymmetric value opportunity. Read why I rate NVO stock a Buy ...
Ozempic maker Novo Nordisk has its worst day since Black Monday
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Novo Nordisk shares dip further as Wegovy gains nearly erased
Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...
Novo Nordisk’s Weight Loss Lesson
Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.
Novo Nordisk expands legal action to protect US patients from unsafe, non-FDA-approved compounded "semaglutide"
Novo Nordisk today announced the filing of 14 new lawsuits to safeguard patients from unsafe and unapproved compounded drugs ...